These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 10586496)

  • 21. Design of a new class of orally active fibrinogen receptor antagonists.
    Klein SI; Molino BF; Czekaj M; Gardner CJ; Chu V; Brown K; Sabatino RD; Bostwick JS; Kasiewski C; Bentley R; Windisch V; Perrone M; Dunwiddie CT; Leadley RJ
    J Med Chem; 1998 Jul; 41(14):2492-502. PubMed ID: 9651154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjugation to hyperbranched polyglycerols improves RGD-mediated inhibition of platelet function in vitro.
    Zhang JG; Krajden OB; Kainthan RK; Kizhakkedathu JN; Constantinescu I; Brooks DE; Gyongyossy-Issa MI
    Bioconjug Chem; 2008 Jun; 19(6):1241-7. PubMed ID: 18476729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.
    Stefanic Anderluh P; Anderluh M; Ilas J; Mravljak J; Sollner Dolenc M; Stegnar M; Kikelj D
    J Med Chem; 2005 May; 48(9):3110-3. PubMed ID: 15857114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of an orally active non-peptide fibrinogen receptor antagonist.
    Stilz HU; Jablonka B; Just M; Knolle J; Paulus EF; Zoller G
    J Med Chem; 1996 May; 39(11):2118-22. PubMed ID: 8667355
    [No Abstract]   [Full Text] [Related]  

  • 25. Activation of caspase-3/caspase-3-like activity in rat cardiomyocytes by an RGD peptide, but not the GPIIb/IIIa antagonist lotrafiban.
    Erhardt JA; Ohlstein EH; Toomey JR; Gabriel MA; Willette RN; Yue TL; Barone FC; Parsons AA
    Thromb Res; 2001 Jul; 103(2):143-8. PubMed ID: 11457472
    [No Abstract]   [Full Text] [Related]  

  • 26. Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.
    Ilić M; Dunkel P; Ilaš J; Chabielska E; Zakrzeska A; Mátyus P; Kikelj D
    Eur J Med Chem; 2013 Apr; 62():329-40. PubMed ID: 23376251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the role of adjacent amino acids to the 313-320 sequence of the alphaIIb subunit on platelet activation and fibrinogen binding to alphaIIbbeta3.
    Mitsios JV; Stamos G; Rodis FI; Tsironis LD; Stanica MR; Sakarellos C; Tsoukatos D; Tsikaris V; Tselepis AD
    Platelets; 2006 Aug; 17(5):277-82. PubMed ID: 16928597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
    J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of glycoprotein IIb/IIIa by crotavirin, a member of disintegrins, prevents platelet from activation and aggregation by Staphylococcus aureus bacteria.
    Liu CZ; Huang HY; Tsai PJ; Shih MH
    Thromb Res; 2005; 116(2):145-55. PubMed ID: 15907530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor.
    Zablocki JA; Miyano M; Garland RB; Pireh D; Schretzman L; Rao SN; Lindmark RJ; Panzer-Knodle SG; Nicholson NS; Taite BB
    J Med Chem; 1993 Jun; 36(13):1811-9. PubMed ID: 8515420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candida albicans and its metabolite gliotoxin inhibit platelet function via interaction with thiols.
    Bertling A; Niemann S; Uekötter A; Fegeler W; Lass-Flörl C; von Eiff C; Kehrel BE
    Thromb Haemost; 2010 Aug; 104(2):270-8. PubMed ID: 20431851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-peptide RGD surrogates which mimic a Gly-Asp beta-turn: potent antagonists of platelet glycoprotein IIb-IIIa.
    Fisher MJ; Gunn B; Harms CS; Kline AD; Mullaney JT; Nunes A; Scarborough RM; Arfsten AE; Skelton MA; Um SL; Utterback BG; Jakubowski JA
    J Med Chem; 1997 Jun; 40(13):2085-101. PubMed ID: 9207949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of RGD analogs as potential vectors for targeted drug delivery.
    Jiang J; Wang W; Sane DC; Wang B
    Bioorg Chem; 2001 Dec; 29(6):357-79. PubMed ID: 11846434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
    Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential inhibition of fibrinogen binding to agonist- and RGDS peptide-activated states of GPIIb-IIIa by an anti-GPIIIa monoclonal antibody, PMA5.
    Nakatanl S; Hato T; Minamoto Y; Fujita S
    Thromb Haemost; 1996 Dec; 76(6):1030-7. PubMed ID: 8972028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptides.
    Wong A; Hwang SM; Johanson K; Samanen J; Bennett D; Landvatter SW; Chen W; Heys JR; Ali FE; Ku TW; Bondinell W; Nichols AJ; Powers DA; Stadel JM
    J Pharmacol Exp Ther; 1998 Apr; 285(1):228-35. PubMed ID: 9536015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous platelet fibrinogen surface expression on activated platelets.
    Gralnick HR; Williams S; McKeown L; Connaghan G; Shafer B; Hansmann K; Vail M; Fenton J
    J Lab Clin Med; 1991 Dec; 118(6):604-13. PubMed ID: 1744509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.